title: Urinary profile of methylprednisolone and its metabolites after oral and topical administrations.
abstract: Methylprednisolone (MP) is prohibited in sports competitions when administered by systemic routes; however its use by topical administration is allowed. Therefore, analytical approaches to distinguish between these different administration pathways are required. A reporting level of 30ng/mL was established for this purpose. However, the suitability of that reporting level for MP is not known. In the present work, excretion profiles of MP and different metabolites after oral and topical administrations have been compared. A method for the quantification of MP and the qualitative detection of fifteen previously reported metabolites has been validated. The method involved an enzymatic hydrolysis, liquid-liquid extraction and analysis by liquid chromatography coupled to tandem mass spectrometry. The method was found to be linear, selective, precise and accurate. The high sensitivity (limit of detection 0.1ng/mL) and linear range (0.1-250ng/mL) achieved allowed for the quantification of MP at both the low concentrations present after topical administration and the high concentrations detected after oral intake. The method was applied to samples collected after oral (4 or 40mg) and topical administration (10mg of MP aceponate/day for 5 consecutive days) to healthy volunteers. After oral administration, MP and all metabolites were detected in urines collected up to at least 36h. Only MP and five metabolites were detected in samples obtained after topical treatment. As expected, concentrations of MP after topical administration were well below current reporting level (30ng/mL), however 3 out of 4 samples in range 8-24h after the low oral dose (4mg) were also below that concentration. Taking into account metabolites detected after both administration routes, metabolites 16β,17α,21-trihydroxy-6α-methylpregna-1,4-diene-3,11,20-trione (M8) and 17α,20α,21-trihydroxy-6α-methylpregna-1,4-diene-3,11-dione (M11) are best markers to differentiate between topical and oral administrations. Their signals after topical administration were lower than those obtained in the first 48h after all oral doses.
authors.affiliation: Bioanalysis Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Doctor Aiguader 88, 08003 Barcelona, Spain. Electronic address: xmatabosch@imim.es.
authors.forename: Xavier
authors.initials: X
authors.lastname: Matabosch
authors.forename: Oscar J
authors.initials: OJ
authors.lastname: Pozo
authors.forename: Núria
authors.initials: N
authors.lastname: Monfort
authors.forename: Clara
authors.initials: C
authors.lastname: Pérez-Mañá
authors.forename: Magi
authors.initials: M
authors.lastname: Farré
authors.forename: Josep
authors.initials: J
authors.lastname: Marcos
authors.forename: Jordi
authors.initials: J
authors.lastname: Segura
authors.forename: Rosa
authors.initials: R
authors.lastname: Ventura
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D002853:Chromatography, Liquid; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000652:urine*; D055815:Young Adult
chemical_list: D008775:Methylprednisolone
keywords: Doping; LC–MS/MS; Metabolites; Methylprednisolone; Routes of administration